← Back to Search

Testosterone Gel for Cancer-Related Fatigue (TEMEC Trial)

Phase 2
Recruiting
Research Sponsored by Seattle Institute for Biomedical and Clinical Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: 55 years and older
Life expectancy of at least 6 months.
Timeline
Screening 1 day
Treatment 6 months
Follow Up 0 days

Summary

This trial is testing whether testosterone replacement can help with cancer-related fatigue in older men who have low testosterone levels.

Who is the study for?
Men aged 55+ with incurable lung or colorectal cancer, experiencing fatigue and low testosterone levels after chemo/radiation therapy. They should have a life expectancy of at least 6 months, not be severely ill from other conditions, and must consent to participate.
What is being tested?
The trial is testing if testosterone gel improves fatigue in older men with cancer compared to a placebo. It's randomized and double-blind, meaning neither the participants nor the researchers know who gets the real treatment until the end.
What are the potential side effects?
Possible side effects include skin irritation where the gel is applied, changes in mood or energy levels, increased red blood cell count which can thicken blood, and potential impacts on prostate health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 55 years old or older.
Select...
You are expected to live for at least 6 more months.
Select...
My testosterone levels are low, below the normal range.

Timeline

Screening ~ 1 day
Treatment ~ 6 months
Follow Up ~0 days
This trial's timeline: 1 day for screening, 6 months for treatment, and 0 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Fatigue change
Secondary study objectives
Change in Sexual Activity Score
Other study objectives
Body Composition Changes
Caregiver Burden Changes
Change in Mood and Well-being
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: testosterone 1.62% gelExperimental Treatment1 Intervention
Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
Group II: placebo gelPlacebo Group1 Intervention
The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.

Find a Location

Who is running the clinical trial?

Seattle Institute for Biomedical and Clinical ResearchLead Sponsor
54 Previous Clinical Trials
13,471 Total Patients Enrolled

Media Library

Placebo Gel Clinical Trial Eligibility Overview. Trial Name: NCT04301765 — Phase 2
Testicular Hypogonadism Research Study Groups: testosterone 1.62% gel, placebo gel
Testicular Hypogonadism Clinical Trial 2023: Placebo Gel Highlights & Side Effects. Trial Name: NCT04301765 — Phase 2
Placebo Gel 2023 Treatment Timeline for Medical Study. Trial Name: NCT04301765 — Phase 2
~47 spots leftby Jan 2026